Search hospitals > Tennessee > Knoxville
University of Tennessee Medical Center
Claim this profileKnoxville, Tennessee 37920
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Obesity
147 reported clinical trials
20 medical researchers
Summary
University of Tennessee Medical Center is a medical facility located in Knoxville, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Obesity and other specialties. University of Tennessee Medical Center is involved with conducting 147 clinical trials across 410 conditions. There are 20 research doctors associated with this hospital, such as Saikrishna Gadde, Timothy J. Panella, Radhakrishnan Ramchandren, M.D., and Neil E. Faulkner.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Saikrishna GaddeUniversity of Tennessee1 year of reported clinical research
Studies Cancer
Studies Bladder Cancer
9 reported clinical trials
23 drugs studied
Timothy J. PanellaUniversity of Tennessee - Knoxville3 years of reported clinical research
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
19 drugs studied
Radhakrishnan Ramchandren, M.D.University of Tennessee2 years of reported clinical research
Studies Lymphoma
Studies Hodgkin's Lymphoma
7 reported clinical trials
13 drugs studied
Neil E. FaulknerUniversity of Tennessee - Knoxville1 year of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
6 reported clinical trials
12 drugs studied
Clinical Trials running at University of Tennessee Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Carcinoma
Bladder Cancer
Gallbladder Cancer
Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Tumors
Imlunestrant
for Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Tennessee Medical Center?
University of Tennessee Medical Center is a medical facility located in Knoxville, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Obesity and other specialties. University of Tennessee Medical Center is involved with conducting 147 clinical trials across 410 conditions. There are 20 research doctors associated with this hospital, such as Saikrishna Gadde, Timothy J. Panella, Radhakrishnan Ramchandren, M.D., and Neil E. Faulkner.